###### Strengths and limitations of this study

-   To the best of our knowledge, this systematic review and meta-analysis will be the first reporting the global epidemiology of acute generalised peritonitis (AGP).

-   This current review will include recent studies, hence, it will inform and guide policy makers in decision making on a global health perspective related to AGP.

-   The absence of language restriction in the methods will allow enrolment of the maximum number of studies published on the topic.

-   A limited number of studies on the topic from some continents, regions or countries could lead to an underestimation of the true global burden of AGP.

Background {#s1}
==========

Acute generalised peritonitis (AGP) is a potentially life-threatening intra-abdominal pathology worldwide which partly manifests as an acute abdomen.[@R1] AGP is the most frequent cause of acute abdomens[@R3] requiring broad-spectrum antibiotics and source control with laparotomy or laparoscopic surgery for definitive cure,[@R5] except in case of spontaneous peritonitis which is a medical emergency treated with antibiotics only.[@R7] Furthermore, AGP is a major contributor to non-trauma deaths in all emergency settings, and the second leading cause of sepsis in critically ill patients.[@R8] Its pathophysiology involves an inflammatory process of the peritoneum caused by an infectious or chemical agent which irritates the peritoneal cavity by either haematogenous spread of infection from another body part to the peritoneal cavity, or by perforation of an intra-abdominal hollow viscus with resultant spillage of bacteria into the peritoneal cavity.[@R3] A robust local inﬂammatory response then stems in to control the inflammation which is mostly infectious in nature. If not treated in time, it spreads to the systemic circulation leading to bacteraemia, septicaemia, septic shock, multiorgan dysfunction and ultimately death.[@R5]

AGP affects about 9.3 patients per 1000 hospital admissions[@R11] and requires adequate preoperative resuscitation to avert high perioperative morbidity and mortality.[@R12] Although AGP is one of the most frequent surgical emergencies at the global level,[@R8] it has been reported to disproportionately affect low-income and middle-income countries especially the sub-Saharan African (SSA) region both in terms of prevalence[@R9] and mortality rates.[@R16] The most common types of AGP in a recent series of 305 cases in SSA were perforated gastroduodenal ulcers, perforated appendicitis and typhoid ileal perforation.[@R9] The postoperative mortality rates of AGP vary between 8.4% and 34% from isolated studies.[@R1] Various aetiologies of AGP that contribute to the death toll in SSA have been described as follows; typhoid perforation of the terminal ileum (34.7 %), postoperative peritonitis (19.5 %) and peptic ulcer perforation (15.2 %), perforated appendicitis (8.7 %), and perforation of the sigmoid colon (8.7 %).[@R9] AGP also poses the problems of hypovolaemic shock, and postoperative complications like surgical site infections, chest infection, intestinal obstruction, postoperative peritonitis, thromboembolic diseases, incisional hernia, wound dehiscence, enterocutanous fistulas, reoperation and prolonged hospital stay.[@R9] AGP increases the risk of perioperative morbidity and mortality, and it incurs a high economic burden on affected patients, families and the health system as a whole.[@R5] It is worth mentioning that AGP can also be iatrogenic after some medical procedures such as continuous ambulatory peritoneal dialysis.[@R21] Despite the tremendous progress in laboratory tests, imagining studies, perioperative resuscitation, surgical techniques and intensive care treatment, the management of AGP is still highly complex and represents a major challenge for all surgical and anaesthetist teams.[@R5]

The above synthesis elucidates that AGP still remains a potentially fatal afﬂiction. With a wide variety of aetiologies, advances in therapies, divergent prevalence data and mortality rates of AGP, it is important to set priorities, funding for surgical interventions and healthcare planning. Hence, it is necessary to have accurate data on the global epidemiology of AGP in order to curb its burden. Hence, to fill these knowledge gaps on the global epidemiology of AGP, we propose this systematic review and meta-analysis protocol to critically synthesise contemporary evidence on the occurrence of AGP in the world. This study will provide the best understanding of the scope of this public health concern and is intended to both inform and draw the attention of surgeons, researchers, public health authorities and governments to this frequent cause of acute abdomen.

Review questions {#s1-1}
----------------

1.  What is the global prevalence of AGP and its different types?

2.  What is the deadliest AGP in the world and the global case fatality rate of AGP?

Objectives {#s1-2}
----------

This systematic review and meta-analysis aims to:

1.  Determine the global prevalence of AGP and its different types.

2.  Determine global and case fatality rate per type of AGP.

Methods and analysis {#s2}
====================

Design and registration {#s2-1}
-----------------------

This systematic review and meta-analysis will be carried out using Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA),[@R23] reported according to PRISMA Protocols[@R24] as illustrated in the [online supplementary file 1](#SP1){ref-type="supplementary-material"}.[@R25]
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Criteria for considering studies for this review {#s2-2}
------------------------------------------------

1.  Types of studies: We will consider cross-sectional, case-control and cohort studies. We will exclude case reports, letters, comments, editorials, experimental studies and case series with less than 30 participants.

2.  Types of participants: We will consider studies conducted on AGP in all age groups (newborns, toddlers, children, adolescents, adults and the elderly) all over the world. Studies conducted in patients selected based on the presence of a specific disease or a condition like HIV infection, chronic liver disease or chronic kidney disease will be excluded.

3.  Type of interventions: medical (antibiotic therapy) or surgical (laparotomy or laparoscopic) treatment.

4.  Types of outcomes: We will consider studies reporting the following outcomes with enough data to compute these estimates: prevalence, types (primary, secondary and tertiary) and the case-fatality rate of AGP. AGP will categorised into primary, secondary or tertiary AGP.[@R20] The primary outcome will be the prevalence of AGP defined as the cases of AGP divided by the total population at a given time period per included study. The secondary outcomes will be the type of AGP and its case fatality rate. Primary AGP also called spontaneous bacterial peritonitis will be defined as community acquired or nosocomially acquired peritonitis caused by haematogenous spread of bactieria or fungi to the peritoneal cavity. Secondary AGP will be defined as peritonitis resulting from an outburst of intra-abdominal viscera such as the stomach, gall bladder, small or large bowels, and appendix with resultant spillage of bacteria from the gastrointestinal tract into the peritoneal cavity.[@R3] Tertiary peritonitis will be defined as peritoneal irritation caused by a penetrating abdominal injury with gastric, intestinal or biliary lesions leading to spillage of bacteria from the gastrointestinal tract into the peritoneal cavity,[@R20] or as an intra-abdominal infection which recurs or persists 48 hours following successful and adequate surgical management of secondary peritonitis.[@R10] The case fatality rate of AGP will be the number of death due to peritonitis divided by the number of patients admitted for peritonitis. Studies with no detailed definition of AGP or a different classification system of AGP to that mentioned above would be described qualitatively.

Search strategy for identifying relevant studies {#s2-3}
------------------------------------------------

The following databases will be considered: *Africa* *n Journal* *s Online*, Americana em Ciências da Saúde, Citation index, EMBASE, Global Index Medicus, Literatura Latino Africa Index Medicus, Medline and Scientific Electronic Library Online from 1 January 2009 to 31 July 2019. We will search records regardless of language of publication. The search strategy for some databases is illustrated in the [online supplementary file 2](#SP2){ref-type="supplementary-material"}. The reference list of the eligible articles and relevant reviews will be manually searched to identify additional studies. Key search terms will include: 'epidemiology', 'peritonitis', 'type' and 'case fatality rate'. Grey literature will also be searched through theses, conference proceedings, book chapters, and governmental and non-governmental organisations reports. We are working hand in glove with a Librarian who designed the search strategy and identified a total number of 7952 articles through this search procedure. The Librarian wishes his name to remain anonymous.
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Selection of studies for inclusion in the review {#s2-4}
------------------------------------------------

Two investigators (NVA and TTFL) will independently select records based on the titles and abstracts. Any disagreement will be solved by discussion and consensus. Studies in languages other than English or French will be translated by a certified translator and considered for eligibility. These investigators will independently evaluate the full text of the selected records. The agreement between the two investigators will be estimated by Cohen\'s κ coefficient.[@R26] Rayyan software will be used for data management in the review selection process.

Methodological quality assessment {#s2-5}
---------------------------------

The methodological quality of the finally included studies will be assessed using the Joanna Briggs Institute tool for prevalence studies ([online supplementary file 3](#SP3){ref-type="supplementary-material"}).[@R27] The defined questions will be scored with 1 for 'Yes' and 0 for 'No' or 'Unclear'. The total score of each article will be calculated by the sum of its points. Based on this tool, studies will be rated as low risk, moderate risk and high risk with scores 0--3, 4--6 and 7--9, respectively. Discrepancy of risk of bias assessment among the six investigators (JNT, NVA, TTFL, AM, DAA and CD) will be solved by discussion and consensus or by arbitration by CD.
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Data extraction and management {#s2-6}
------------------------------

Data extraction will be done independently by five investigators (JNT, NVA, TTFL, AM and CD). Disagreements among each pair of investigators will be solved by discussion or will involve, if necessary, a third review author for arbitration (DAA). Using a pretested form, we will extract: the last name of the first author, year of publication, region, country's name, study area (rural or urban), study setting, country, number of study sites (one site, multicentre), period of inclusion of participants, timing of data collection (retrospective or prospective), mean or median age, male proportion, study design, sample size, delay between diagnosis and treatment (\< or \>24 hours), American Society of Anesthesiologists grade (I, II, III, IV and V), any type of shock (septic, hypovolaemic or mixed) on admission, the type of AGP (tuberculosis peritonitis, fungal peritonitis, appendicular peritonitis, typhoid ileal peritonitis, peptic ulcer peritonitis, peritonitis due to bowel injury, etc), specific characteristics of the study population (patients with HIV, diabetes mellitus, inflammatory bowel diseases, cancer, organ transplants or any other specific condition), management options (antibiotic therapy, laparotomy, laparoscopy), Mannheim Peritonitis Index prevalence and case fatality rate of AGP. For multicentre studies conducted in different countries, the prevalence, types and case fatality rate of AGP will be reported for the individual countries. The countries will be grouped in regions according to the WHO regional classification: Africa, Americas, Eastern Mediterranean, Europe, South-East Asia and Western Pacific. Where relevant outcome estimates will not be available, we will contact the corresponding author of the study to request the missing information via emails. If no response is obtained from the corresponding author after two sent emails in a time frame of 1 month, the study will be excluded.

Data synthesis and analysis {#s2-7}
---------------------------

Data analyses will be done using the 'meta' package of R (V.3.2.2). Unadjusted prevalence will be recalculated based on the information of crude numerators and denominators provided by individual studies. We will then perform random-effects meta-analyses.[@R28] To keep the effect of studies with extremely small or extremely large prevalence estimates, the variance of the study-specific prevalence will be stabilised with Freeman-Tukey double arcsine transformation before pooling the data.[@R29] Heterogeneity will be evaluated by the χ² test on Cochrane's Q statistics,[@R30] and quantified by I² values.[@R31] In case heterogeneity is encountered, subgroup analyses will be performed according to the income level of the country, the type of peritonitis, its aetiology and the WHO region. Publication and selection bias will be assessed visually by inspection of the funnel plot. The presence of publication bias will be detected by the formal Egger's test .[@R32] A value of p\<0.10 on Egger's test will be considered indicative of statistically significant publication bias.

Protocol development and potential amendments {#s2-8}
---------------------------------------------

No funder, sponsor or institution was involved in the conception and design of this protocol. We do not plan to make any changes to this protocol. However, if substantial changes occur during the review, they will be reported in the published results.

Patient and public involvement {#s2-9}
------------------------------

Patients and public were not involved in the conception and design of this protocol.
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